•Fetal Abnormalities Due to Anticonvulsants;•Are Manufacturers' Recommended Doses Too High?;•Mood Disorders Associated with Interferon Therapy;•Prochlorperazine and Extrapyramidal Reactions;•Gynecomastia and AIDS Drugs;•Toxicity of Lithium Combined with Angiotensin II Receptor Blockers

Abstract

The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), to discuss methods of prevention, and to promote reporting of ADRs to the FDA's medWatch program (1-800-FDA-1088). If you have reported an interesting preventable ADR to medWatch, please consider sharing the account with our readers.

Get full access to this article

View all access options for this article.

References

Shuster

Adverse drug reactions. Hosp Pharm. 2001; 36: 497–502.

Holmes

L.B.

The teratogenicity of anticonvulsant drugs. N Engl J Med. 2001; 344: 1132–8.

Chen

J.S.

Dose discrepancies between the Physicians' Desk Reference and the medical literature, and their possible role in the high incidence of dose-related adverse drug events. Arch Intern Med. 2001; 161: 957–64.

Malek-Ahmadi

Mood disorders associated with interferon treatment: Theoretical and practical considerations. Ann Pharmacother. 2001; 35: 489–95.

Vinson

D.R.

Frequency of adverse reactions to prochlorperazine in the ED: A response [letter]. Am J Emerg Med. 2001; 19: 175.

Olsen

J.C.

, Keng

J.A.

, Clark

J.A.

Frequency of adverse reactions to prochlorperazine in the ED. Am J Emerg Med. 2000; 18: 609–11.

Manfredi

, Calza

, Chiodo

Gynecomastia associated with highly active antiretro-viral therapy. Ann Pharmacother. 2001; 35: 438–9.

Zwanzger

Lithium intoxication after administration of AT1 blockers [letter]. J Clin Psych. 2001; 62: 208–9.